 CADX | Cadence Pharmaceuticals Inc. announced the closing of its previously announced public offering of 21.8 million shares of its common stock, including 2.8 million shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters, at a public offering price of $3.75 per share. The net proceeds from the offering, after deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be $77.4 million. |
Recent Events: Issue Equity
Cadence Pharma Closes 21.8M Shares Offering
November 23, 2011
